Impact of the selective A2_AR and A2_BR dual antagonist AB928/etrumadenant on CAR T cell function.

ABSTRACT:

Background

Chimeric antigen receptor (CAR) T cell therapy has been successfully translated to clinical practice for the treatment of B cell malignancies. The suppressive microenvironment of many malignancies is a bottleneck preventing treatment success of CAR T cells in a broader range of tumours. Among others, the immunosuppressive metabolite adenosine is present in high concentrations within many tumours and dampens anti-tumour function of immune cells and consequently therapeutic response.

Methods

Here, we present the impact of the selective adenosine A2_A and A2_B receptor antagonist AB928/etrumadenant on CAR T cell cytokine secretion, proliferation, and cytotoxicity. Using phosphorylation-specific flow cytometry, we evaluated the capability of AB928

SUBMITTER: Seifert M 

PROVIDER: S-EPMC9726885 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature